Ardelyx, Inc. (ARDX)
$3.19+2.24%Close
SELLBEAR · day 11
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $788M
- Beta
- 0.68
- P/E (TTM)
- -14.13
- Short % float
- 11.67%
- Days to cover
- 6.6
- SI change
- +8.1%
- 1W
- -2.15%
- 1M
- -6.18%
- vs SPY 1W
- -2.01%
- vs SPY 1M
- -8.68%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 49
- VALUE
- 16
- GROWTH
- 40
- GARP
- 82
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-21.6%
REV YoY-
ROE-36.0%
EPS YoY-
ROA-9.7%
GROSS94
OP-8
NET-12
[VALUATION]
P/E TTM-14.13
P/E FWD14.25
SECTOR PE20.48
INDUSTRY PE13.99
P/B5.31
P/FCF-
EV/EBITDA-38.35
EV/EBIT-
PEG0.16
FCF YIELD-
RISK
INT COV-
D/E171.92
ALTMAN Z-
CURR RATIO3.34
ND/EBITDA-
BETA0.68
Company news
FAQ
- What is LOPJLB’s current signal on ARDX?
- LOPJLB’s latest quantitative signal on Ardelyx, Inc. (ARDX) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ARDX in?
- Ardelyx, Inc. (ARDX) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Ardelyx, Inc. (ARDX) do?
- Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed P…